Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 628

1.

Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.

Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, Saba NF, Pakkala S, Patel PR, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M, Higgins KA.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30156-1. doi: 10.1016/j.cllc.2019.06.014. [Epub ahead of print]

PMID:
31296433
2.

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.

Cancer Med. 2019 Jul 3. doi: 10.1002/cam4.2375. [Epub ahead of print]

3.

Improving knowledge of doctors and paramedics through effective bone procurement workshop: A cognitive approach.

Mohd S, Yusof N, Lai LL, Hossain MG, Ramalingam S, Hamid SSA, Ng WM, Mansor A.

BMC Med Educ. 2019 Jul 1;19(1):238. doi: 10.1186/s12909-019-1685-9.

4.

Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.

Bhargava N, Jaitly S, Goswami SG, Jain S, Chakraborty D, Ramalingam S.

Stem Cell Res. 2019 Jun 14;39:101484. doi: 10.1016/j.scr.2019.101484. [Epub ahead of print]

5.

Corrigendum to "Comparative study of the physicochemical, nutritional, and antioxidant properties of some commercial refined and non-centrifugal sugars". [Food Research International 109 (2018) 614-625].

Lee JS, Ramalingam S, Jo IG, Kwon YS, Bahuguna A, Oh YS, Kwon OJ, Kim M.

Food Res Int. 2019 Aug;122:563. doi: 10.1016/j.foodres.2018.06.037. Epub 2018 Jun 28. No abstract available.

PMID:
31229113
6.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934. [Epub ahead of print]

PMID:
31154919
7.

Antioxidant potential of theaflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin - induced diabetic rats.

Gothandam K, Ganesan VS, Ayyasamy T, Ramalingam S.

Redox Rep. 2019 Dec;24(1):41-50. doi: 10.1080/13510002.2019.1624085.

PMID:
31142215
8.

End-of-Life Practices in Rural South India: SocioCultural Determinants.

Ramalingam S, Ganesan S.

Indian J Palliat Care. 2019 Apr-Jun;25(2):224-227. doi: 10.4103/IJPC.IJPC_173_18.

9.

DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Teneng I, Picchi MA, Leng S, Dagucon CP, Ramalingam S, Tellez CS, Belinsky SA.

DNA Repair (Amst). 2019 Jul;79:1-9. doi: 10.1016/j.dnarep.2019.04.006. Epub 2019 Apr 27.

PMID:
31055244
10.

Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1's elimination during colon cancer development and progression.

Roy BC, Ahmed I, Ramalingam S, Jala V, Haribabu B, Ramamoorthy P, Ashcraft J, Valentino J, Anant S, Sampath V, Umar S.

Oncotarget. 2019 Mar 22;10(24):2340-2354. doi: 10.18632/oncotarget.26684. eCollection 2019 Mar 22.

11.

Pleotropic role of RNA binding protein CELF2 in autophagy induction.

New J, Subramaniam D, Ramalingam S, Enders J, Sayed AAA, Ponnurangam S, Standing D, Ramamoorthy P, O'Neil M, Dixon DA, Saha S, Umar S, Gunewardena S, Jensen RA, Thomas SM, Anant S.

Mol Carcinog. 2019 Aug;58(8):1400-1409. doi: 10.1002/mc.23023. Epub 2019 Apr 24.

PMID:
31020708
12.

Phosphorene-gold nanocomposite based microfluidic aptasensor for the detection of okadaic acid.

Ramalingam S, Chand R, Singh CB, Singh A.

Biosens Bioelectron. 2019 Jun 15;135:14-21. doi: 10.1016/j.bios.2019.03.056. Epub 2019 Apr 5.

PMID:
30981975
13.

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.

Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X.

Mol Cancer. 2019 Apr 10;18(1):85. doi: 10.1186/s12943-019-1012-4.

14.

Characterisation of graphene electrodes for microsystems and microfluidic devices.

Del Rosso M, Brodie CH, Ramalingam S, Cabral DM, Pensini E, Singh A, Collier CM.

Sci Rep. 2019 Apr 8;9(1):5773. doi: 10.1038/s41598-019-42108-x.

15.

Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies.

Sabarimurugan S, Kumarasamy C, Madurantakam Royam M, Lakhotiya K, Kodiveri Muthukaliannan G, Ramalingam S, Jayaraj R.

Medicine (Baltimore). 2019 Mar;98(12):e14570. doi: 10.1097/MD.0000000000014570.

16.

Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity.

Sukhatme VV, Ramalingam SS, Ahmed R, Sukhatme VP.

Cancer J. 2019 Mar/Apr;25(2):88-99. doi: 10.1097/PPO.0000000000000368.

PMID:
30896530
17.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

PMID:
30876831
18.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.

J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.

PMID:
30872388
19.

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations.

Shi P, Zhang S, Zhu L, Qian G, Ren H, Ramalingam SS, Chen M, Sun SY.

Transl Oncol. 2019 May;12(5):705-713. doi: 10.1016/j.tranon.2019.02.006. Epub 2019 Mar 9.

20.

Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.

Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, Chen Z, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF.

Head Neck. 2019 May;41(5):1490-1498. doi: 10.1002/hed.25379. Epub 2019 Mar 5. Review.

PMID:
30835900
21.

The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.

Ramalingam S, Ramamurthy VP, Gediya LK, Murigi FN, Purushottamachar P, Huang W, Choi EY, Zhang Y, Vasaitis TS, Kane MA, Lapidus RG, Njar VCO.

Cancers (Basel). 2019 Mar 3;11(3). pii: E299. doi: 10.3390/cancers11030299.

22.

A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.

Gill HS, Ramalingam SS.

Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996. [Epub ahead of print] No abstract available.

PMID:
30825394
23.

Clinical prognostic model for older patients with advanced non-small cell lung cancer.

Ganti AK, Wang X, Stinchcombe TE, Wang Y, Bradley J, Cohen HJ, Kelly K, Paulus R, Ramalingam SS, Vokes EE, Pang H.

J Geriatr Oncol. 2019 Jul;10(4):555-559. doi: 10.1016/j.jgo.2019.02.007. Epub 2019 Feb 21.

PMID:
30797707
24.

The CRISPR/Cas9 System for Targeted Genome Engineering in Free-Living Fungi: Advances and Opportunities for Lichenized Fungi.

Shanmugam K, Ramalingam S, Venkataraman G, Hariharan GN.

Front Microbiol. 2019 Feb 7;10:62. doi: 10.3389/fmicb.2019.00062. eCollection 2019. Review.

25.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Apr;42(4):331-336. doi: 10.1097/COC.0000000000000524.

PMID:
30789414
26.

Periodontal therapy as an adjunctive modality for HbA1c reduction in type-2 diabetic patients.

Sundar C, Ramalingam S, Mohan V, Pradeepa R, Ramakrishnan MJ.

J Educ Health Promot. 2018 Dec 28;7:152. doi: 10.4103/jehp.jehp_66_18. eCollection 2018.

27.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
28.

Anti-dengue activity of Andrographis paniculata extracts and quantification of dengue viral inhibition by SYBR green reverse transcription polymerase chain reaction.

Ramalingam S, Karupannan S, Padmanaban P, Vijayan S, Sheriff K, Palani G, Krishnasamy KK.

Ayu. 2018 Apr-Jun;39(2):87-91. doi: 10.4103/ayu.AYU_144_17.

29.

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2019 May;14(5):876-889. doi: 10.1016/j.jtho.2019.01.020. Epub 2019 Feb 5.

PMID:
30735816
30.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00736-0. [Epub ahead of print]

PMID:
30725388
31.

A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold.

Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A.

Sci Rep. 2019 Jan 31;9(1):1015. doi: 10.1038/s41598-018-37703-3.

32.

Association between viral seasonality and meteorological factors.

Price RHM, Graham C, Ramalingam S.

Sci Rep. 2019 Jan 30;9(1):929. doi: 10.1038/s41598-018-37481-y.

33.

Adsorption of Proteins on Dual Loaded Silica Nanocapsules.

Ramalingam S, Le Bourdon G, Pouget E, Scalabre A, Rao JR, Perro A.

J Phys Chem B. 2019 Feb 21;123(7):1708-1717. doi: 10.1021/acs.jpcb.8b12028. Epub 2019 Feb 12.

PMID:
30689387
34.

Are Body Image Issues Affecting Our Adolescents? A Cross-sectional Study among College Going Adolescent Girls.

Ganesan S, Ravishankar SL, Ramalingam S.

Indian J Community Med. 2018 Dec;43(Suppl 1):S42-S46. doi: 10.4103/ijcm.IJCM_62_18.

35.

Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.

Ramamoorthy P, Thomas SM, Kaushik G, Subramaniam D, Chastain KM, Dhar A, Tawfik O, Kasi A, Sun W, Ramalingam S, Gunewardena S, Umar S, Mammen JM, Padhye SB, Weir SJ, Jensen RA, Sittampalam GS, Anant S.

Cancer Res. 2019 Apr 1;79(7):1681-1695. doi: 10.1158/0008-5472.CAN-18-2602. Epub 2019 Jan 23.

PMID:
30674533
36.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

PMID:
30659024
37.

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.

Carlisle JW, Ramalingam SS.

Future Oncol. 2019 Mar;15(8):805-816. doi: 10.2217/fon-2018-0626. Epub 2019 Jan 18. Review.

PMID:
30657347
38.

Subarachnoid haemorrhage.

Shipman KE, Ramalingam SK, Dawson CH, Yasear ZA.

Clin Med (Lond). 2019 Jan;19(1):88-89. doi: 10.7861/clinmedicine.19-1-88a. No abstract available.

39.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.

PMID:
30624547
40.

Graph theoretical analysis, in silico modeling, prediction of toxicity, metabolism and synthesis of novel 2-(methyl/phenyl)-3-(4-(5-substituted-1,3,4-oxadiazol-2-yl) phenyl) quinazolin-4(3H)-ones as NMDA receptor inhibitor.

Saravanan G, Panneerselvam T, Kunjiappan S, Parasuraman P, Alagarsamy V, Udayakumar P, Soundararajan M, Joshi SD, Ramalingam S, Ammunje DN.

Drug Dev Res. 2019 May;80(3):368-385. doi: 10.1002/ddr.21511. Epub 2019 Jan 4.

PMID:
30609096
41.

Growing my practice, keeping up with medical knowledge, and handling adverse outcomes.

Ramalingam S.

Clin Adv Hematol Oncol. 2018 Nov;16(11):764-765. No abstract available.

PMID:
30543591
42.

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS.

J Clin Oncol. 2019 Jan 20;37(3):222-229. doi: 10.1200/JCO.18.00264. Epub 2018 Dec 5.

PMID:
30523756
43.

A banner year for immunotherapy and targeted therapy.

Carlisle JW, Ramalingam SS.

Nat Rev Clin Oncol. 2019 Feb;16(2):79-80. doi: 10.1038/s41571-018-0138-4. No abstract available.

PMID:
30538305
44.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

45.

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G.

Cancer. 2019 Mar 15;125(6):892-901. doi: 10.1002/cncr.31891. Epub 2018 Dec 4.

PMID:
30512189
46.

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).

Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ.

Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.

PMID:
30442588
47.

The Efficacy of Recombinant Platelet-Derived Growth Factor on Beta-Tricalcium Phosphate to Regenerate Femoral Critical Sized Segmental Defects: Longitudinal In Vivo Micro-CT Study in a Rat Model.

Badwelan M, Alkindi M, Ramalingam S, Nooh N, Al Hezaimi K.

J Invest Surg. 2018 Nov 15:1-13. doi: 10.1080/08941939.2018.1519048. [Epub ahead of print]

PMID:
30430878
48.

Genome-wide analysis of purple acid phosphatase (PAP) family proteins in Jatropha curcas L.

Venkidasamy B, Selvaraj D, Ramalingam S.

Int J Biol Macromol. 2019 Feb 15;123:648-656. doi: 10.1016/j.ijbiomac.2018.11.027. Epub 2018 Nov 7.

PMID:
30414420
49.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.

PMID:
30329148
50.

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer.

Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, Petros JA, Saad F, Moreno CS.

Cancers (Basel). 2018 Oct 11;10(10). pii: E379. doi: 10.3390/cancers10100379.

Supplemental Content

Loading ...
Support Center